Document Detail


A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
MedLine Citation:
PMID:  21239048     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer.
METHODS: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75 mg/m²) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45 Gy)± brachytherapy and three additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS).
RESULTS: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age=58 years (range: 21-81 years). 78% (32/41)=endometrioid histology. Stages=10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent=1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Seven patients died following treatment with a median follow-up of 28 months (range: 7-70 months). KM estimates and 95% confidence intervals for OS at 1 year were 95% (82-99%), at 3 years 90% (75-96%), and at 5 years 71% (45-86%). Of the 39 with primary disease, 11 progressed or died within 5 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 87% (72-94%), at 3 years 71% (51-83%), and at 5 years 64% (42-80%).
CONCLUSIONS: "Sandwiching" radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.
Authors:
Melissa A Geller; Joseph J Ivy; Rahel Ghebre; Levi S Downs; Patricia L Judson; Linda F Carson; Amy L Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P Boente; Peter A Argenta
Related Documents :
20223508 - Clinical outcome in metastatic renal cell carcinoma patients after failure of initial v...
21852508 - Palliative radiation therapy in the treatment of canine appendicular synovial sarcoma.
24512858 - A phase ii open-label study of ganetespib, a novel heat shock protein 90 inhibitor for ...
9667278 - Oral chemotherapy: rationale and future directions.
12053718 - Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the ...
22623448 - End-stage renal disease and critical limb ischemia: a deadly combination?
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-01-15
Journal Detail:
Title:  Gynecologic oncology     Volume:  121     ISSN:  1095-6859     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-22     Completed Date:  2011-05-16     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  112-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA. gelle005@umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects
Brachytherapy / adverse effects
Carboplatin / administration & dosage,  adverse effects
Carcinoma, Endometrioid / drug therapy*,  pathology,  radiotherapy*
Combined Modality Therapy / adverse effects
Disease-Free Survival
Dose Fractionation
Endometrial Neoplasms / drug therapy*,  pathology,  radiotherapy*
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Recurrence, Local / drug therapy*,  radiotherapy*
Neoplasm Staging
Taxoids / administration & dosage,  adverse effects
Young Adult
Grant Support
ID/Acronym/Agency:
P30 CA77598/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Taxoids; 15H5577CQD/docetaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synergistic toxic effect of nano-TiO(2) and As(V) on Ceriodaphnia dubia.
Next Document:  Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow-up o...